OCUP Ocuphire Pharma Inc

Price (delayed)

$2

Market cap

$41.16M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.03

Enterprise value

$24.13M

Ocuphire is a publicly traded, clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders. Ocuphire's pipeline currently includes two small- molecule product ...

Highlights
Ocuphire Pharma's debt has shrunk by 100% QoQ
The company's EPS has surged by 87% YoY and by 21% QoQ
The quick ratio has contracted by 42% YoY and by 14% from the previous quarter
Ocuphire Pharma's equity has decreased by 35% YoY and by 15% QoQ

Key stats

What are the main financial stats of OCUP
Market
Shares outstanding
20.58M
Market cap
$41.16M
Enterprise value
$24.13M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.65
Price to sales (P/S)
79.77
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
49.35
Earnings
Revenue
$489,000
EBIT
-$22.05M
EBITDA
-$22.05M
Free cash flow
-$19.21M
Per share
EPS
-$1.03
Free cash flow per share
-$0.98
Book value per share
$0.75
Revenue per share
$0.03
TBVPS
$0.92
Balance sheet
Total assets
$17.9M
Total liabilities
$3.3M
Debt
$0
Equity
$14.6M
Working capital
$14.59M
Liquidity
Debt to equity
0
Current ratio
5.41
Quick ratio
5.19
Net debt/EBITDA
0.77
Margins
EBITDA margin
-4,509.2%
Gross margin
100%
Net margin
-4,512.3%
Operating margin
-4,463.8%
Efficiency
Return on assets
-100.7%
Return on equity
-118.2%
Return on invested capital
N/A
Return on capital employed
-151.1%
Return on sales
-4,510%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

OCUP stock price

How has the Ocuphire Pharma stock price performed over time
Intraday
-1.96%
1 week
-2.44%
1 month
-15.25%
1 year
-60.71%
YTD
-46.38%
QTD
4.17%

Financial performance

How have Ocuphire Pharma's revenue and profit performed over time
Revenue
$489,000
Gross profit
$489,000
Operating income
-$21.83M
Net income
-$22.07M
Gross margin
100%
Net margin
-4,512.3%
Ocuphire Pharma's net margin has surged by 93% YoY but it has decreased by 9% QoQ
The operating margin has surged by 84% year-on-year but it has declined by 9% since the previous quarter
The company's net income has surged by 67% YoY and by 9% QoQ
The operating income has grown by 23% YoY and by 9% from the previous quarter

Growth

What is Ocuphire Pharma's growth rate over time

Valuation

What is Ocuphire Pharma stock price valuation
P/E
N/A
P/B
2.65
P/S
79.77
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
49.35
The company's EPS has surged by 87% YoY and by 21% QoQ
Ocuphire Pharma's equity has decreased by 35% YoY and by 15% QoQ
The P/B is 20% below the last 4 quarters average of 3.3 and 17% below the 5-year quarterly average of 3.2
OCUP's P/S is 24% below its last 4 quarters average of 105.6
The revenue is down by 17% since the previous quarter

Efficiency

How efficient is Ocuphire Pharma business performance
The company's return on sales has surged by 93% YoY but it fell by 9% QoQ
Ocuphire Pharma's return on equity has surged by 89% YoY
OCUP's ROA has soared by 76% YoY

Dividends

What is OCUP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for OCUP.

Financial health

How did Ocuphire Pharma financials performed over time
The current ratio has declined by 42% year-on-year and by 15% since the previous quarter
The quick ratio has contracted by 42% YoY and by 14% from the previous quarter
Ocuphire Pharma's debt is 100% lower than its equity
Ocuphire Pharma's debt has shrunk by 100% QoQ
OCUP's debt to equity has dropped by 100% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.